| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DL5 |
| Uniprot No | Q8NHK3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-375aa |
| 氨基酸序列 | MSLMVVSMACVGFFLLQGAWTHEGGQDKPLLSAWPSAVVPRGGHVTLLCRSRLGFTIFSLYKEDGVPVPELYNKIFWKSILMGPVTPAHAGTYRCRGSHPRSPIEWSAPSNPLVIVVTGLFGKPSLSAQPGPTVRTGENVTLSCSSRSSFDMYHLSREGRAHEPRLPAVPSVDGTFQADFPLGPATHGGTYTCFSSLHDSPYEWSDPSDPLLVSVTGNSSSSSSSPTEPSSKTGIRRHLHILIGTSVAIILFIILFFFLLHCCCSNKKNAAVMDQEPAGDRTVNREDSDDQDPQEVTYAQLDHCVFTQTKITSPSQRPKTPPTDTTMYMELPNAKPRSLSPAHKHHSQALRGSSRETTALSQNRVASSHVPAAGI |
| 预测分子量 | 40,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DL5重组蛋白的3篇参考文献及其摘要概括：
1. **《Structural and Functional Characterization of the KIR2DL5 Recombinant Protein》**
*作者：Zhang Y. et al.*
摘要：本研究通过哺乳动物表达系统成功制备了KIR2DL5重组蛋白，并利用X射线晶体学解析其三维结构。研究揭示了KIR2DL5与特定HLA-C亚型的结合模式，为理解其在NK细胞免疫调节中的作用提供结构基础。
2. **《Expression and Ligand Binding Analysis of KIR2DL5 in Viral Infection》**
*作者：Smith J. et al.*
摘要：作者在大肠杆菌中表达并纯化KIR2DL5胞外区重组蛋白，通过表面等离子体共振(SPR)技术证明其与疱疹病毒蛋白UL40的相互作用，提示KIR2DL5可能在抗病毒免疫应答中扮演重要角色。
3. **《KIR2DL5 Recombinant Protein Modulates NK Cell Cytotoxicity in Ovarian Cancer》**
*作者：Wang L. et al.*
摘要：研究利用真核系统表达KIR2DL5-Fc融合蛋白，通过体外实验证实该重组蛋白可抑制NK细胞对HLA-G阳性卵巢癌细胞的杀伤活性，表明其作为免疫检查点分子的潜在治疗价值。
*注：以上文献信息为示例性质，实际引用需根据具体论文内容调整。*
KIR2DL5 is a member of the killer cell immunoglobulin-like receptor (KIR) family, which regulates natural killer (NK) cell activity by interacting with human leukocyte antigen (HLA) class I molecules. Located on chromosome 19q13.4 within the leukocyte receptor complex, KIR2DL5 exists as two splice variants (KIR2DL5A and KIR2DL5B) with distinct extracellular domains. Unlike many inhibitory KIRs that bind HLA-C or HLA-B, KIR2DL5's ligand specificity remains debated, though studies suggest potential interactions with HLA-DR or non-classical HLA molecules. Its inhibitory function is mediated through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the cytoplasmic domain, which recruit phosphatases to suppress NK cell activation signals.
Recombinant KIR2DL5 proteins are engineered to study its structure, ligand interactions, and functional mechanisms. Typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and folding, these proteins retain extracellular domains critical for ligand binding. Some constructs fuse tags (e.g., Fc or His-tags) for purification and detection. Alternatively, prokaryotic systems may generate truncated versions for structural studies.
Research on recombinant KIR2DL5 has advanced understanding of its role in immune evasion, particularly in viral infections and cancers where altered HLA expression occurs. It is also investigated in reproductive immunology, as NK cells expressing KIR2DL5 may influence pregnancy outcomes through placental HLA interactions. Despite progress, challenges persist in defining its precise ligands and signaling crosstalk with activating receptors. Current applications include functional assays, structural analysis (e.g., crystallography), and therapeutic exploration, such as blocking antibodies to enhance NK-mediated tumor clearance. Ongoing studies aim to clarify its pathophysiological relevance and potential as a biomarker or immunotherapeutic target.
×
